Evicenter
MarkdownMedical informationP&T meetings
Adrabetadex (Lembaz)

Infantile-onset Niemann-Pick disease type C

Also known as VTS-270
Last updated
196 sources

Clinical evidence

Expanded access program

62 evidence topics · 16 sources

Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using rescored 4-domain NPC clinical severity scale as the disease progression outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Participants enrolled, December 2021
FieldDashboard
Current patients enrolled in Expanded Access Program“50 patients”
Description of analysis sets
Results
Participant disposition
Time since first dose and discontinuations in the expanded access program
MeasureAll EAP (n=86)
Time since first treatment dose, median [IQR], months“52.8 [15.4, 74.2]”
TEAE leading to discontinuation, n (%)“3 (3.5)”
TEAE leading to death, n (%)“6 (7.0)”
Baseline characteristics
Baseline characteristics of all expanded access participants
CharacteristicAll EAP (N=86)
Neurological onset <2 years, n (%)“26 (30.2)”
Neurological onset 2 to 6 years, n (%)“23 (26.7)”
Neurological onset ≥6 years, n (%)“29 (33.7)”
Age at onset missing, n (%)“8 (9.3)”
Age at neurological symptom onset, median (Q1, Q3), years (n=78)“3.5 (1.5, 7.0)”
Age at adrabetadex treatment start, median (Q1, Q3), years (n=78)“8.0 (3.0, 20.0)”
Male, n (%)“51 (59.3)”
Female, n (%)“34 (39.5)”
White, n (%)“76 (88.4)”
Miglustat use at baseline, yes, n (%)“33 (38.4)”
Miglustat use at baseline, no, n (%)“46 (53.5)”
Baseline characteristics of treated participants with infantile onset in the disease burden analysis
CharacteristicOverall (N=76)
Neurological onset <2 years, n (%)“33 (43.4)”
Neurological onset 2 to <6 years, n (%)“43 (56.6)”
Age at neurological symptom onset, mean (SD), years“2.5 (1.56)”
Age at adrabetadex treatment start, mean (SD), years“7.7 (5.56)”
Age at adrabetadex treatment start, median (Q1, Q3), years“6.2 (3.2, 10.8)”
Male, n (%)“41 (53.9)”
White, n (%)“66 (86.8)”
Baseline R4DNPCCSS, mean (SD)“7.2 (5.06)”
Baseline R4DNPCCSS, median (Q1, Q3)“7.0 (3.0, 10.0)”
Baseline characteristics by time from onset to treatment
CharacteristicTreatment initiation <1 year from onset (n=9)Treatment initiation ≥1 year from onset (n=16)
Age at neurological symptom onset, mean (SD), years“2.11 (1.563)”“2.65 (1.494)”
Age at adrabetadex treatment start, mean (SD), years“2.70 (1.614)”“7.15 (3.838)”
Duration from onset to treatment, mean (SD), years“0.59 (0.324)”“4.50 (3.308)”
Miglustat use at baseline, yes, n (%)“1 (11.1)”“9 (56.3)”
Baseline R4DNPCCSS, median (Q1, Q3)“1.50 (0.50, 2.50)”“5.00 (2.00, 10.00)”
Duration of treatment exposure, mean (SD), weeks“348.37 (54.297)”“397.23 (93.427)”
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events in the expanded access program by combination therapy group
MeasureAdrabetadex first, adrabetadex-only period (n=28)Any combination exposure, combination period (n=33)No combination after adrabetadex (n=53)All EAP (n=86)
With ≥1 TEAE (any grade), n (%)“28 (100)”“23 (69.7)”“48 (90.6)”“81 (94.2)”
Leading to death, n (%)“0”“1 (3.0)”“5 (9.4)”“6 (7.0)”
Serious AEs, n (%)“13 (46.4)”“8 (24.2)”“24 (45.3)”“41 (47.7)”
Grade ≥3, n (%)“9 (32.1)”“6 (18.2)”“21 (39.6)”“33 (38.4)”
TEAEs of interest, n (%)“22 (78.6)”“9 (27.3)”“35 (66.0)”“62 (72.1)”
Ataxia, n (%)“10 (35.7)”“5 (15.2)”“23 (43.4)”“37 (43.0)”
Fatigue, n (%)“17 (60.7)”“7 (21.2)”“25 (47.2)”“47 (54.7)”
Hearing impairment, n (%)“10 (35.7)”“2 (6.1)”“15 (28.3)”“26 (30.2)”
Hearing loss, post-dose ataxia and tiredness, and lumbar puncture events in the first three expanded access patients
Study limitations
Summary: design limitations of the expanded access program analyses
  • Control and setting: the original report of three patients names as limitations “the lack of a control group” and treatment through an expanded access protocol with likely more confounding changes from optimizing support and other treatments than in a clinical trial. Enrollment required that participants be ineligible for all currently enrolling clinical trials.
  • Population counts: the prescribing information describes 85 participants (71 treatment-naïve and 14 previously treated) with a mean (SD) treatment duration of 44 (32) months.
  • Dosing: doses started at 200 mg or 400 mg based on age, with titration up to 1200 mg in the initial protocol or 900 mg in the later revision, and dose adjustments were allowed.
  • External comparison and analysis sets: the survival analysis by baseline disease burden compared 80 adrabetadex-treated participants with I-NPC (neurological onset <6 years) from clinical studies or the expanded access program with an untreated cohort of 44 from the NIH natural history study. Four treated participants without a baseline R4DNPCCSS score were excluded, leaving 76. Baseline was the last observation before the first dose for treated participants and the first available observation for the untreated cohort, and the authors state that “no matching procedure was performed between treated and untreated participants.”
  • Prompt versus delayed treatment: the analysis included only participants with onset <6 years of age who had sustained treatment for at least 5 years, 9 with treatment initiation <1 year and 16 with initiation ≥1 year from onset, and miglustat use at baseline was 1 (11.1%) and 9 (56.3%), respectively. The company compared progression in these 25 participants with published natural history data.
  • Combination therapy analysis: participants exposed to combination therapy had a shorter time since first treatment dose, as most started those therapies when they became commercially available at the end of 2024. Safety data were collected only while participants were in the study and receiving adrabetadex, and were not available for other NPC therapies received before enrollment.
  • Concomitant miglustat: all three patients in the original report went on miglustat at the same age as diagnosis, and its authors state that an effect of miglustat or of the combination on progression cannot be ruled out. In the CSF neuron-specific enolase study, most participants receiving intrathecal HPβCD were also on miglustat, which the authors state makes it challenging to attribute the decrease to HPβCD alone.
  • Sample size: the long-term 24(S)-hydroxycholesterol study included 10 individuals, and its authors state that its conclusions are limited by its small size; the CSF neuron-specific enolase study used a subset of ten expanded access participants.